[HTML][HTML] The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high‐risk kidney transplant recipients
A Humar, Y Lebranchu, F Vincenti, EA Blumberg… - American Journal of …, 2010 - Elsevier
Late‐onset cytomegalovirus (CMV) disease is a significant problem with a standard 3‐month
prophylaxis regimen. This multicentre, double‐blind, randomized controlled trial compared …
prophylaxis regimen. This multicentre, double‐blind, randomized controlled trial compared …
Результаты профилактики цитомегаловирусной инфекции валганцикловиром у пациентов с трансплантированной почкой
ЕИ Прокопенко, ЕО Щербакова, АВ Ватазин… - Клиническая …, 2013 - elibrary.ru
Цель. Оценить эффективность профилактики активной цитомегаловирусной инфекции
(ЦМВ-инфекции) в посттрансплантационном периоде препаратом валганцикловир …
(ЦМВ-инфекции) в посттрансплантационном периоде препаратом валганцикловир …
Valganciclovir in cytomegalovirus prophylaxis in renal transplant recipients
EI Prokopenko, EO Shcherbakova… - Clinical …, 2013 - cardiosomatics.orscience.ru
Aim. Estimation of efficacy of prophylaxis of cytomegalovirus infection with valganciclovir in
renal transplant recipients. Methods. Retrospective study included 349 renal transplant …
renal transplant recipients. Methods. Retrospective study included 349 renal transplant …
Board Certification
F Pierre, S Dakota - vetmed.iastate.edu
Abbreviated Curriculum Vitae Jennifer A. Schleining-Cerfogli Updated 4/4/2012 Education: BS
(Agriculture), 1999, South Dakota St Page 1 Abbreviated Curriculum Vitae Jennifer A …
(Agriculture), 1999, South Dakota St Page 1 Abbreviated Curriculum Vitae Jennifer A …